On June 18, 2026 Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL gene silencing technology to eliminate cancer, reported that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company’s INTASYL siRNA platform, including its lead clinical candidate PH-762 for the treatment of cutaneous carcinomas. The presentation will conclude with a live question and answer session, providing attendees the opportunity to engage directly. In addition, Mr. Bitterman will be available for one-on-one meetings on June 24-25, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We look forward to participating in the Life Sciences Investor Forum, where we will discuss why we believe INTASYL represents a differentiated and promising approach in immuno-oncology," said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.
One-on-One Meetings: Phio’s availability is June 24-25, 2026
Phio’s Presentation and live Q&A : Thursday June 25, 2026, at 3 PM EDT
REGISTER HERE: Phio Pharmaceuticals Corp. (NASDAQ: PHIO)
The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in real time. A replay of the webcast will be available following the conclusion of the conference.
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more about the event at www.virtualinvestorconferences.com.
(Press release, Phio Pharmaceuticals, JUN 18, 2026, View Source [SID1234668800])